EVAg

COVID19: antiviral compounds test results

This section is dedicated to preclinical evaluation of molecules with antiviral potential against the SARS-CoV-2.
It may receive links to important published articles in the field, but also preprints and reports of (still) unpublished data.
In particular, it is important to report negative results that may not deserve publication but can anyway be useful for the community.

The site is open to contributions by EVA-GLOBAL partners and external scientists. For EVA-GLOBAL partners, submission is not moderated and can be performed by sending documents to our data manager ( ) . For external partners, please send documents to our expert board ( ) who will moderate submissions.
We would appreciate receiving contributions in a format close to the first contributions. Please pay attention to providing an adequate description of methods.


List of compounds test results: (click on the blue column headers to sort the corresponding columns)
Compound name Brand Name Result Type Results summary Related Publication Test results file Post datesort descending
Favipiravir / t-705 Favilavir and Avifavir preprint When treatment was initiated before or simultaneously to infection, favipiravir had a strong dose effect, leading to dramatic reduction of infectious titers in lungs and clinical alleviation of the disease. The antiviral efficacy observed in this study was achieved with plasma drug exposure comparable with those previously found during human clinical trials and was associated with weight losses in animals. Thereby, pharmacokinetic and tolerance studies are required to determine whether similar effects can be safely achieved in humans PDF icon Favipiravir.pdf July 17, 2020
Hydroxychloroquine Plaquenil, Axemal, Dolquine and Quensyl publication Our findings do not support the use of HCQ, either alone or in combination with AZTH, as an antiviral drug for the treatment of COVID-19 in humans July 22, 2020
Prestwick Chemical library (1520 compounds) publication 90 compounds were identified as positive hits from the screen and remain to be validated more precisely in vitro and evaluated and in vivo August 4, 2020
Ondansetron Zophren preliminary report Ondansetron was found to inhibit SARS-CoV-2 replication in vitro using Vero-E6 cells. However, results obtained using a hamster model suggest that this molecule is a poor inhibitor of SARS-CoV-2 replication in vivo PDF icon Ondansetron.pdf October 7, 2020
Mirtazapine Norset and Remeron preliminary report Mirtazapine was found as a primary HIT in our screen and thus a potential inhibitor of SARS-CoV-2 replication. However, results obtained using a hamster model suggest that this molecule is a poor inhibitor of SARS-CoV-2 replication in vivo PDF icon Mirtazapine.pdf October 7, 2020
Olmesartan Belsar and Olmetec preliminary report Olmesartan was found as a primary HIT during the screen but then show poor efficiency in our RNA yield reduction assay. Moreover, results obtained using a hamster model suggest that this molecule is a poor inhibitor of SARS-CoV-2 replication in vivo PDF icon Olmesartan.pdf October 7, 2020
6-MercaptoPurine Purinethole and Xaluprine preliminary report 6-mercaptopurine was found to inhibit SARS-CoV-2 replication in vitro using Vero-E6 cells. However, results obtained using a hamster model suggest that this molecule is a poor inhibitor of SARS-CoV-2 replication in vivo PDF icon 6-mercaptopurine.pdf October 19, 2020
Nabumetone Nabucox preliminary report Nabumetone was found to inhibit SARS-CoV-2 replication in vitro using Vero-E6 cells. However, results obtained using a hamster model suggest that this molecule is a poor inhibitor of SARS-CoV-2 replication in vivo PDF icon Nabumetone.pdf October 19, 2020
N-acétyl L-cystéine (NAC) ISTENDO, HIDONAC and Exomuc preliminary report Results obtained in VeroE6 suggest that this compound does not inhibit SARS-CoV-2 replication in vitro. PDF icon N-acétyl L-cystéine (NAC).pdf October 19, 2020
Nelfinavir Viracept preliminary report Nelfinavir was found to inhibit SARS-CoV-2 replication in vitro using Vero-E6 cells. However, results obtained using a hamster model suggest that this molecule is a poor inhibitor of SARS-CoV-2 replication in vivo PDF icon Nelfinavir.pdf October 19, 2020
Telmisartan Micardis and Pritor preliminary report Telmisartan was found to slightly inhibit SARS-CoV-2 replication in vitro using Vero-E6 cells. However, results obtained using a hamster model suggest that this molecule is a poor inhibitor of SARS-CoV-2 replication in vivo PDF icon Telmisartan.pdf October 19, 2020
Raloxifene Evista and Optruma preliminary report Raloxifene was found to inhibit SARS-CoV-2 replication in vitro using Vero-E6 and Caco-2 cells. However, results obtained using a hamster model suggest that this molecule is a poor inhibitor of SARS-CoV-2 replication in vivo PDF icon Raloxifene.pdf October 19, 2020
Connexion